Tag Archives: BIO International Convention

Phase III Assets in High Demand – Results from the Business Forum Meeting Activity

Picture1-thumb

At the BIO International Convention in Boston today, we released our results from the Business Forum meeting activity. This analysis provides a real-time snapshot of what in-licensors from pharma and biotech are looking for here at the conference. The Business Forum hit over 25,000 scheduled One-on-One Partnering™ meetings on Monday afternoon.  This is 18% more meetings than last year, and more than double the meetings held back in 2007, when we last held this event in Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , ,

What’s the Buzz?

BuzzofBIOLogo

Meet Deuteria Pharmaceuticals, winner of the 2012 Buzz of BIO competition. What is Buzz of BIO? Companies from around the world enter for the chance to win free registration and a company presentation in the BIO Business Forum. Who won? Deuteria Pharmaceuticals, Inc., a company that is pioneering ‘Deuterium-Enabled Chiral Switching’ (DECS) to improve the profile of drugs that interconvert between enantiomers both in vitro and in vivo. Stabilizing the preferred isomer improves the product Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , ,

We Are BIO

Jim Greenwood

Here’s what the Biotechnology Industry Organization is doing for you. This year, we challenged you to answer the question – What’s Your BIO? On behalf of the Biotechnology Industry Organization (BIO), I’d like to answer that question to illustrate how we advocate for federal, state and global policies to foster continued biotech breakthroughs, innovation and ingenuity. In addition to producing the BIO International Convention, we educate and engage public policy leaders in Washington, in state Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , , ,

BIO 2012 Super Session Recap: Ernst & Young’s Beyond Borders

Ernst & Young

The fanfare surrounding this morning’s unveiling of Ernst & Young’s 26th annual report on the state of the biotech industry, Beyond Borders, was buoyed by positive trends outlined in the report that show despite the overall lingering uneasiness in the economy, biotech is continuing its growth momentum. The Super Session at the 2012 BIO International Convention was moderated by members of Ernst & Young’s life sciences leadership team: Glen Giovannetti, Gautam Jaggi and Sanjeev Wadhwa; Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Prior User Rights and Trade Secrets

AA049539

By Joe Allen, President, Allen and Associates One theme of the day is the cloud of uncertainity overhanging the US patent system. This was underscored in the Prior User Rights and Trade Secrets session at the 2012 BIO International Convention as well. The new prior user rights defense which came into effect with enactment of the America Invents Act (AIA) was very differently viewed by the small biotech company perspective given by Mary Ann Dillahunty (Oncolytics Read More >

Patently BIOtech  |  1 Comment  |  Email This Post
Tags: , , , , , , ,